幹細胞製造市場は、予測期間中に13.16％のCAGRを達成すると予想されます。幹細胞治療は、AIDS、心血管疾患、神経変性疾患、自己免疫感染症、筋肉疾患、創傷修復など、すでに治癒が困難な多くの感染症に対する治療薬となる可能性があります。幹細胞は、脊髄損傷、パーキンソン病、アルツハイマー感染症、その他の神経学的問題によってもたらされた損傷したニューロンに取って代わるために、徐々に利用されています。同様に、糖尿病患者にインスリンを投与し、損傷した組織や臓器の回復を助けるという緊急の役割も担っています。
一部の人々に影響を与え、注目を集めている疾患は患者数が限られていることと、治療法の開発に多額の費用がかかるため、無視されることがよくあります。これらの疾患には、まれな腫瘍、遺伝性疾患、抵抗力のない熱帯感染症、変性感染症などが含まれます。2020 年 2 月にFDAが発表した情報によると、珍しい病気が約 7,000 件あり、その一部は子供に影響を与えています。それにもかかわらず、これらの感染症のうち、FDA が承認した医薬品があるのはわずか 5% です。その後、さまざまな感染症の治療のための幹細胞応用に対する意識の高まりと、希少な疾患の発症率が、市場の発展をさらに加速させる中心点となっています。
目次
TABLE OF CONTENTS
1 EXECUTIVE SUMMARY
2 MARKET INTRODUCTION
2.1 SCOPE OF THE STUDY
2.2 RESEARCH OBJECTIVE
2.3 MARKET STRUCTURE
2.4 ASSUMPTIONS & LIMITATIONS
3 RESEARCH METHODOLOGY
3.1 DATA MINING
3.2 SECONDARY RESEARCH
3.3 PRIMARY RESEARCH
3.4 BREAKDOWN OF PRIMARY RESPONDENTS
3.5 FORECASTING TECHNIQUES
3.6 RESEARCH METHODOLOGY FOR MARKET SIZE ESTIMATION
3.6.1 BOTTOM-UP APPROACH
3.6.2 TOP-DOWN APPROACH
3.7 DATA TRIANGULATION
3.8 VALIDATION
4 MARKET DYNAMICS
4.1 OVERVIEW
4.2 DRIVERS
4.2.1 GROWING AWARENESS REGARDING THE USAGE OF STEM CELLS FOR TREATING VARIOUS DISEASES
4.2.2 INCREASING PREVALENCE OF RARE DISEASES
4.2.3 TECHNOLOGICAL ADVANCEMENTS IN STEM CELL MANUFACTURING
4.3 RESTRAINTS
4.3.1 RISKS ASSOCIATED WITH UNPROVEN STEM CELL TREATMENTS
4.3.2 HIGHER OPERATIONAL COSTS ASSOCIATED WITH STEM CELL MANUFACTURING AND BANKING
4.4 OPPORTUNITIES
4.4.1 INCREASING PUBLIC AND PRIVATE FUNDING FOR STEM CELL-BASED RESEARCH
5 MARKET FACTOR ANALYSIS
5.1 VALUE CHAIN ANALYSIS
5.1.1 R&D AND DESIGNING
5.1.2 MANUFACTURING
5.1.3 DISTRIBUTION & SALES
5.1.4 POST-SALES REVIEW
5.2 PORTER'S FIVE FORCES MODEL
5.2.1 THREAT OF NEW ENTRANTS
5.2.2 BARGAINING POWER OF SUPPLIERS
5.2.3 BARGAINING POWER OF BUYERS
5.2.4 INTENSITY OF RIVALRY
5.2.5 THREAT OF SUBSTITUTES
5.3 IMPACT OF COVID-19
5.3.1 IMPACT ON SUPPLY CHAIN
5.3.2 IMPACT ON PRODUCTION
5.3.3 IMPACT ON DEMAND-SUPPLY GAP ANALYSIS
5.3.4 IMPACT ON R&D
6 GLOBAL STEM CELL MANUFACTURING MARKET, BY PRODUCT
6.1 OVERVIEW
6.2 STEM CELL LINES
6.3 INSTRUMENTS
6.4 CULTURE MEDIA
6.5 CONSUMABLES
7 GLOBAL STEM CELL MANUFACTURING MARKET, BY APPLICATION
7.1 OVERVIEW
7.2 RESEARCH
7.3 TARGET IDENTIFICATION
7.4 STEM CELL-BASED THERAPY
7.5 CELL AND TISSUE BANKING
8 GLOBAL STEM CELL MANUFACTURING MARKET, BY END USER
8.1 OVERVIEW
8.2 PHARMACEUTICAL AND BIOTECHNOLOGY COMPANIES
8.3 HOSPITALS
8.4 STEM CELL BANKS
8.5 OTHERS
9 GLOBAL STEM CELL MANUFACTURING MARKET, BY REGION
9.1 OVERVIEW
9.2 NORTH AMERICA
9.2.1 US
9.2.2 CANADA
9.3 EUROPE
9.3.1 GERMANY
9.3.2 FRANCE
9.3.3 UK
9.3.4 ITALY
9.3.5 SPAIN
9.3.6 REST OF EUROPE
9.4 ASIA-PACIFIC
9.4.1 CHINA
9.4.2 INDIA
9.4.3 JAPAN
9.4.4 SOUTH KOREA
9.4.5 AUSTRALIA
9.4.6 REST OF ASIA-PACIFIC
9.5 REST OF THE WORLD
9.5.1 MIDDLE EAST
9.5.2 AFRICA
9.5.3 LATIN AMERICA
10 COMPETITIVE LANDSCAPE
10.1 OVERVIEW
10.2 COMPETITIVE BENCHMARKING
10.3 MAJOR GROWTH STRATEGY IN STEM CELL MANUFACTURING MARKET
10.4 THE LEADING PLAYER IN TERMS OF NUMBER OF DEVELOPMENTS IN STEM CELL MANUFACTURING MARKET
10.5 KEY DEVELOPMENT ANALYSIS
10.6 KEY DEVELOPMENTS & GROWTH STRATEGIES
10.6.1 PRODUCT APPROVALS AND PRODUCT LAUNCHES
10.6.2 PARTNERSHIP/COLLABORATION
10.6.3 BUSINESS EXPANSIONS/AGREEMENTS
10.6.4 MERGERS & ACQUISITIONS
11 COMPANY PROFILES
11.1 ABBVIE, INC.
11.1.1 COMPANY OVERVIEW
11.1.2 FINANCIAL OVERVIEW
11.1.3 PRODUCTS OFFERED
11.1.4 KEY DEVELOPMENTS
11.1.5 SWOT ANALYSIS
11.1.6 KEY STRATEGIES
11.2 BIO-RAD LABORATORIES, INC.
11.2.1 COMPANY OVERVIEW
11.2.2 FINANCIAL OVERVIEW
11.2.3 PRODUCTS OFFERED
11.2.4 KEY DEVELOPMENTS
11.2.5 SWOT ANALYSIS
11.2.6 KEY STRATEGIES
11.3 FUJIFILM HOLDINGS CORPORATION (FUJIFILM CELLULAR DYNAMICS, INC.)
11.3.1 COMPANY OVERVIEW
11.3.2 FINANCIAL OVERVIEW
11.3.3 PRODUCTS OFFERED
11.3.4 KEY DEVELOPMENTS
11.3.5 KEY STRATEGIES
11.4 BECTON DICKINSON AND COMPANY
11.4.1 COMPANY OVERVIEW
11.4.2 FINANCIAL ANALYSIS
11.4.3 PRODUCTS OFFERED
11.4.4 KEY DEVELOPMENTS
11.4.5 KEY STRATEGIES
11.5 THERMO FISHER SCIENTIFIC INC.
11.5.1 COMPANY OVERVIEW
11.5.2 FINANCIAL ANALYSIS
11.5.3 PRODUCTS OFFERED
11.5.4 KEY DEVELOPMENTS
11.5.5 SWOT ANALYSIS
11.5.6 KEY STRATEGIES
11.6 LONZA GROUP
11.6.1 COMPANY OVERVIEW
11.6.2 FINANCIAL ANALYSIS
11.6.3 PRODUCTS OFFERED
11.6.4 KEY DEVELOPMENTS
11.6.5 KEY STRATEGIES
11.7 BRISTOL-MYERS SQUIBB COMPANY
11.7.1 COMPANY OVERVIEW
11.7.2 FINANCIAL OVERVIEW
11.7.3 PRODUCTS OFFERED
11.7.4 KEY DEVELOPMENTS
11.7.5 KEY STRATEGIES
11.8 GLAXOSMITHKLINE PLC
11.8.1 COMPANY OVERVIEW
11.8.2 FINANCIAL OVERVIEW
11.8.3 PRODUCTS OFFERED
11.8.4 KEY DEVELOPMENTS
11.8.5 SWOT ANALYSIS
11.8.6 KEY STRATEGIES
11.9 SARTORIUS AG
11.9.1 COMPANY OVERVIEW
11.9.2 FINANCIAL OVERVIEW
11.9.3 PRODUCTS OFFERED
11.9.4 KEY DEVELOPMENTS
11.9.5 KEY STRATEGIES
11.10 MERCK KGAA
11.10.1 COMPANY OVERVIEW
11.10.2 FINANCIAL OVERVIEW
11.10.3 PRODUCTS OFFERED
11.10.4 KEY DEVELOPMENTS
11.10.5 KEY STRATEGIES
11.11 TAKEDA PHARMACEUTICAL COMPANY LIMITED
11.11.1 COMPANY OVERVIEW
11.11.2 FINANCIAL OVERVIEW
11.11.3 PRODUCTS OFFERED
11.11.4 KEY DEVELOPMENTS
11.11.5 SWOT ANALYSIS
11.11.6 KEY STRATEGIES
12 APPENDIX
12.1 REFERENCES
12.2 RELATED REPORTS
